The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.
G. Kristensen
Consultant or Advisory Role - Roche
T. Perren
No relevant relationships to disclose
W. Qian
No relevant relationships to disclose
J. Pfisterer
No relevant relationships to disclose
J. A. Ledermann
No relevant relationships to disclose
F. Joly
No relevant relationships to disclose
M. S. Carey
No relevant relationships to disclose
P. J. Beale
No relevant relationships to disclose
A. Cervantes
No relevant relationships to disclose
A. M. Oza
No relevant relationships to disclose